Seroatlas · Human Serome Atlas

SLC17A6

Vesicular glutamate transporter 2

Also known as: DNPI, VGLU2_HUMAN, VGLUT2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9P2U8
Gene
SLC17A6
Ensembl
ENSG00000091664
Chromosome
11
Canonical length
582 aa
Protein class
Metabolic proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

Enables L-glutamate uniporter activity. Involved in L-glutamate import and phosphate ion homeostasis. Located in synaptic vesicle membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

582 residues, UniProt reviewed canonical sequence.

>Q9P2U8|SLC17A6
     1  MESVKQRILA PGKEGLKNFA GKSLGQIYRV LEKKQDTGET IELTEDGKPL EVPERKAPLC
    61  DCTCFGLPRR YIIAIMSGLG FCISFGIRCN LGVAIVDMVN NSTIHRGGKV IKEKAKFNWD
   121  PETVGMIHGS FFWGYIITQI PGGYIASRLA ANRVFGAAIL LTSTLNMLIP SAARVHYGCV
   181  IFVRILQGLV EGVTYPACHG IWSKWAPPLE RSRLATTSFC GSYAGAVIAM PLAGILVQYT
   241  GWSSVFYVYG SFGMVWYMFW LLVSYESPAK HPTITDEERR YIEESIGESA NLLGAMEKFK
   301  TPWRKFFTSM PVYAIIVANF CRSWTFYLLL ISQPAYFEEV FGFEISKVGM LSAVPHLVMT
   361  IIVPIGGQIA DFLRSKQILS TTTVRKIMNC GGFGMEATLL LVVGYSHTRG VAISFLVLAV
   421  GFSGFAISGF NVNHLDIAPR YASILMGISN GVGTLSGMVC PIIVGAMTKN KSREEWQYVF
   481  LIAALVHYGG VIFYAIFASG EKQPWADPEE TSEEKCGFIH EDELDEETGD ITQNYINYGT
   541  TKSYGATTQA NGGWPSGWEK KEEFVQGEVQ DSHSYKDRVD YS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC17A6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
16 nTPM

Expression across tissuesHPA

Tissue

  • hypothalamus: 16 nTPM
  • retina: 7.3 nTPM
  • midbrain: 4.5 nTPM
  • amygdala: 4.4 nTPM
  • cerebral cortex: 3.9 nTPM
  • pituitary gland: 3.5 nTPM

Single-cell type

  • retinal ganglion cells: 77 nCPM
  • lactotrophs: 65 nCPM
  • somatotrophs: 55 nCPM
  • brain excitatory neurons: 48 nCPM
  • other brain neurons: 31 nCPM
  • thyrotrophs: 26 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • thalamus: 86 nTPM
  • pons: 83 nTPM
  • medulla oblongata: 49 nTPM
  • hypothalamus: 39 nTPM
  • midbrain: 36 nTPM
  • cerebellum: 30 nTPM

ReferencesPubMed · IEDB

Publications for SLC17A6 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

3 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.47
gnomAD pLI
0.16
gnomAD missense Z
1.54
DepMap mean gene effect
0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC17A6 as an antibody target. Whether an autoantibody or antibody against SLC17A6 could matter depends on whether native SLC17A6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC17A6 is annotated at the cell surface, where native SLC17A6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC17A6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC17A6. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...